TrialAnnals of the rheumatic diseases2024
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment.
Eugen Feist et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
10 papers cite it
this paperpooled ittrialcites it